Introduction Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) represent one of the most transformative pharmacologic developments in metabolic medicine
While many peptides are considered safe when used appropriately, potential side effects can vary depending on the type, dosage and method of administration
Observed molecular and cellular responses are highly dependent on experimental conditions, concentration, exposure duration, and model system
Butyrate is the key metabolite that unifies and supports the benefits of this synbiotic system.*1-3
These may include excessive thirst, skin conditions, blurry vision, abdominal cramps, nausea, vomiting, and increased risk of severe side effects for individuals with existing health conditions